Enliven Therapeutics Inc. has synthesized HER2 (erbB2) inhibitors, including Exon 20 insertion (Ex20Ins) mutant inhibitors, reported to be useful for the treatment of cancer.
Vertex Pharmaceuticals Inc. has disclosed apolipoprotein L1 (APOL1) inhibitors reported to be useful for the treatment of focal segmental glomerulosclerosis and pancreatic cancer.
Researchers from Bristol Myers Squibb Co. recently discussed the discovery and preclinical characterization of a series of Toll-like receptor 7 (TLR7) agonists with potential as anticancer drug candidates.
Molecular glue degraders are compounds intended to prompt the degradation of E3 ubiquitin ligases by engaging and modifying their surface. Molecular glue-induced protein degradation is considered an emerging strategy in drug discovery.
Uniqure NV has received FDA clearance of its IND application for AMT-260, the company’s gene therapy candidate that represents a potential one-time administered approach to treating refractory mesial temporal lobe epilepsy (MTLE).
Beactica Therapeutics AB has selected BEA-17 as a preclinical candidate from its lysine demethylase 1 (LSD1) program targeting aggressive brain tumors and other cancers, and IND-enabling toxicology studies will now be initiated.
Researchers from Ashvattha Therapeutics LLC recently reported on ASH-41020, a new dendranib compound acting as a CSF-1R inhibitor with anti-inflammatory and immunomodulatory effects.
Investigators at Cold Spring Harbor Laboratory have discovered a method of switching cancerous rhabdomyosarcoma cells back into normal muscle cells that could lead to the development of a treatment for this rare aggressive childhood cancer.
RSS
